ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0343

Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry

Christine Bacha1, Anne Dennos2, Andrea Knight3, Laura Schanberg4, Mary Beth Son5, Emily von Scheven6, Shahla Amin7, Charles Helmick8 and Aimee Hersh9, 1Nationwide Children's Hospital, Grandview Heights, OH, 2Duke University, Durham, NC, 3Hospital for Sick Children, Toronto, ON, Canada, 4Duke University Medical Center, Durham, NC, 5Boston Children's Hospital, Brookline, MA, 6University of California San Francisco, San Francisco, CA, 7CARRA, Durham, NC, 8Centers for Disease Control and Prevention, Atlanta, GA, 9University of Utah, Salt Lake City, UT

Meeting: ACR Convergence 2021

Keywords: Epidemiology, longitudinal studies, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multi-center, observational registry that collects demographic, clinical, and provider- and patient-reported data from patients with pediatric-onset rheumatic diseases in North America, Israel and Italy. This study aimed to describe the demographic features, cumulative clinical manifestations, and treatments of the childhood systemic lupus erythematosus (cSLE) cohort within the CARRA Registry.

Methods: Since 2015, the CARRA Registry has enrolled 10,411 patients at 70 centers. Childhood-onset SLE enrollment began in March 2017. We performed a retrospective cohort study of patients with cSLE enrolled in the US between March 2017 to December 2020. Inclusion criteria for participants in the CARRA cSLE Registry include: 1) diagnosis of cSLE at < 18 years based on American College of Rheumatology (ACR) or Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria; 2) enrollment within two years of cSLE diagnosis or at the time of a flare of lupus nephritis; and 3) enrollment prior to 21 years of age. Sociodemographic and clinical data were summarized using descriptive statistics.

Results: The current registry cohort includes 671 participants with cSLE. The majority are female (85%) with mean age at enrollment of 14.3 (SD 2.9) years. The cohort is both ethnically and racially diverse (Table 1). Socioeconomic status varies widely, noting 12.5% having a household income below $25,000/year. The median time from symptom onset to diagnosis was two months (interquartile range (IQR) 25 days to 6 months), from diagnosis to enrollment was 5 (IQR 1-15) months, and from enrollment to end of follow up was 14 (IQR 6 to 23) months. At the end of the follow-up period, more than 60% of participants developed nephritis as defined by ACR or SLICC criteria. 6.1% and 10% had neurological manifestations per ACR and SLICC criteria, respectively (Table 2). Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at enrollment was a median of 4 (IQR 2-10). Most patients were prescribed hydroxychloroquine. In the first 2-3 years of disease, participants received a variety of immunosuppressive therapies including Mycophenolate Mofetil, Cyclophosphamide, Azathioprine, Rituximab, Belimumab and disease modifying anti-rheumatic drugs such as Leflunomide and Methotrexate. 84% of patients were prescribed either oral or intravenous glucocorticoids during their disease course (Table 3).

Conclusion: The CARRA Registry has enrolled a racially and ethnically diverse cohort of cSLE patients in the early course of their disease. These participants exhibit moderate disease activity and although the use of hydroxychloroquine in this cohort is high, a significant proportion of patients are utilizing glucocorticoids at the last study visit. We anticipate enrolling a minimum of 1000 participants with more than ten years of follow-up. This cohort, which is one of the Centers for Disease Control (CDC) funded SLE registries, provides a unique opportunity to describe the natural history, treatments, and outcomes in patients with cSLE.


Disclosures: C. Bacha, None; A. Dennos, None; A. Knight, None; L. Schanberg, UCB, 12, DSMB member, Sanofi, 12, DSMB member, SOBI, 2, BMS, 5; M. Son, None; E. von Scheven, None; S. Amin, None; C. Helmick, None; A. Hersh, None.

To cite this abstract in AMA style:

Bacha C, Dennos A, Knight A, Schanberg L, Son M, von Scheven E, Amin S, Helmick C, Hersh A. Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/overview-of-the-childhood-systemic-lupus-erythematosus-csle-cohort-in-the-carra-registry/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/overview-of-the-childhood-systemic-lupus-erythematosus-csle-cohort-in-the-carra-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences